Mapping the Future: A Content Analysis of the Evolution of Gene Therapy in Urological Cancer
DOI:
https://doi.org/10.51601/ijhp.v5i1.404Abstract
Background: Gene Therapy Has Emerged As A Promising Approach In The Treatment Of Urological Cancers, Including Prostate, Kidney, And Bladder Cancers. Over The Past Decade, Significant Advancements Have Been Made In Gene Editing Technologies Such As Crispr-Cas9, Rna-Based Therapies, And Viral Vector Systems. These Innovations Offer Precise Targeting Of Oncogenes And Tumor Suppressor Genes, Potentially Improving Treatment Efficacy And Reducing Adverse Effects Compared To Conventional Therapies. Methods: A Systematic Content Analysis Was Conducted On Peer-Reviewed Literature And Clinical Trial Reports From 2015 To 2025. Databases Such As Pubmed, Sciencedirect, And Scopus Were Used To Extract Relevant Studies. Inclusion Criteria Encompassed Original Research Articles, Systematic Reviews, And Clinical Trials Focused On Gene Therapy Applications In Prostate, Kidney, And Bladder Cancer. Studies Exclusively Conducted On In Vitro Or Animal Models Without Clinical Relevance Were Excluded. Results: Crispr-Cas9 Has Demonstrated High Precision In Gene Editing, Particularly In Prostate Cancer, Where Targeting Androgen Receptor-Related Genes Has Enhanced Hormone Therapy Sensitivity. Rna Therapy, Especially Using Sirna Targeting Vegf And Hif-1α, Has Shown Promise In Kidney Cancer Treatment By Inhibiting Angiogenesis. Viral Vectors Remain A Primary Method For Gene Delivery In Bladder Cancer, Although Immune Responses Pose A Significant Challenge. Clinical Trials Indicate That Gene Therapy Combined With Immunotherapy, Particularly Checkpoint Inhibitors Like Pembrolizumab, Enhances Treatment Efficacy. However, Regulatory Barriers, High Costs (Estimated At Over $500,000 Per Patient), And Safety Concerns Regarding Off-Target Effects Remain Major Obstacles To Widespread Clinical Implementation. Conclusion: Despite These Challenges, Gene Therapy Holds Great Potential For Revolutionizing Urological Cancer Treatment. Future Research Should Focus On Optimizing Gene Delivery Systems, Reducing Off-Target Risks, And Developing Cost-Effective Production Methods. Personalized Gene Therapy Approaches, Leveraging Advancements In Genomic Sequencing, Are Expected To Further Enhance Treatment Precision. With Continued Innovation And Regulatory Advancements, Gene Therapy Is Anticipated To Become An Integral Part Of Standard Urological Cancer Care In The Coming Decade.
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33.
Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096.
Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576(7785):149-57.
Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014;157(6):1262-78.
Dai W, Wang F, Lu Y, Gong J, Li Q, Wang W, et al. Advances in RNA-based therapeutics for cancer treatment. Adv Drug Deliv Rev. 2021;168:1-25.
Chen X, Zou F, Hu W, Xiong M, Meng X, Lin X, et al. CRISPR/Cas9 for cancer therapy: opportunities and challenges. Cancer Lett. 2019;447:48-55.
Slack FJ, Chinnaiyan AM. The role of non-coding RNAs in oncology. Cell. 2019;179(5):1033-55.
Li Y, Jiang X, Zhang Y, Gao Z, Liu Y, Chen Y, et al. Challenges and strategies in developing CRISPR-based gene therapies. J Gene Med. 2022;24(6):e3412.
Naldini L. Gene therapy returns to the forefront. Nat Rev Genet. 2015;16(6):331-2.
Chandrasekar T, Yang JC, Gao AC, Evans CP. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 2015;4(3):365-80.
Charlesworth CT, Deshpande PS, Dever DP, Camarena J, Lemgart VT, Cromer MK, et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med. 2019;25(2):249-54.
Zhang C, Konermann S, Brideau NJ, Lotfy P, Wu X, Novick SJ, et al. A human ortholog of archaeal Argonaute functions as a RNA-guided nuclease. Nature. 2021;593(7859):446-51.
Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA statement. PLoS Med. 2009;6(7):e1000097.
Barrangou R, Doudna JA. Applications of CRISPR technologies in research and beyond. Nat Biotechnol. 2016;34(9):933-41.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33.
Zhao L, Zhang Y, Wang Z, He T, Zou D. PTEN silencing by CRISPR/Cas9 promotes prostate cancer progression. Mol Cancer Res. 2019;17(2):409-19.
Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203-22.
Ginn SL, Amaya AK, Alexander IE, Edelstein M, Abedi MR. Gene therapy clinical trials worldwide to 2017: An update. J Gene Med. 2018;20(5):e3015.
Chira S, Gulei D, Hajitou A, Zimta AA, Cordelier P, Berindan-Neagoe I. CRISPR/Cas9: Transcending the reality of genome editing. Mol Ther Nucleic Acids. 2017;7:211-22.
Kaelin WG Jr. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer. 2008;8(11):865-73.
Patel SA, Minn AJ. Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies. Immunity. 2018;48(3):417-33.
Yin H, Kauffman KJ, Anderson DG. Delivery technologies for genome editing. Nat Rev Drug Discov. 2017;16(6):387-99.
van den Berg JH, Heemskerk B, van Rooij N, van den Broek D, Simons J, Camps M, et al. Tumor infiltrating lymphocytes in the treatment of metastatic melanoma and other solid tumors. J Immunol Res. 2017;2017:9251519.
Ledford H. CRISPR treatment inserted directly into the body for first time. Nature. 2020;579(7798):185.
Smargon AA, Cox DBT, Pyzocha NK, Zheng K, Slaymaker IM, Gootenberg JS, et al. Cas13b is a type VI-B CRISPR-associated RNA-guided RNA nuclease. Science. 2017;356(6333):438-42.
Yin H, Kauffman KJ, Anderson DG. Delivery technologies for genome editing. Nat Rev Drug Discov. 2017;16(6):387-99.
Cox DBT, Gootenberg JS, Abudayyeh OO, Franklin B, Kellner MJ, Joung J, et al. RNA editing with CRISPR-Cas13. Science. 2017;358(6366):1019-27.
van den Berg JH, Heemskerk B, van Rooij N, van den Broek D, Simons J, Camps M, et al. Tumor infiltrating lymphocytes in the treatment of metastatic melanoma and other solid tumors. J Immunol Res. 2017;2017:9251519.
Charlesworth CT, Deshpande PS, Dever DP, Camarena J, Lemgart VT, Cromer MK, et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med. 2019;25(2):249-54.
Naldini L. Gene therapy returns to the forefront. Nat Rev Genet. 2015;16(6):331-2.
Fendler A, Bauer D, Busch J, Jung K. Challenges and prospects of CRISPR/Cas9 in prostate cancer research. Biochem Biophys Res Commun. 2021;578:116-23.
Chandrasekar T, Yang JC, Gao AC, Evans CP. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 2015;4(3):365-80.
Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096.
Tycko J, Myer VE, Hsu PD. Methods for optimizing CRISPR-Cas9 genome editing specificity. Mol Cell. 2016;63(3):355-70.
Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016;533(7603):420-4.
Zuckerman JE, Hsueh T, Koya RC, Davis ME, Ribas A. siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide. J Invest Dermatol. 2011;131(2):453-60.
Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater.2021;6(12):1078-94.
Kotterman MA, Chalberg TW, Schaffer DV. Viral vectors for gene therapy: translational and regulatory considerations. Annu Rev Biomed Eng. 2015;17:63-89.
Ferreira MV, Cabral T, Fialho SL, Fernandes RAF, Silva-Cunha A. Advances in viral vector-based ocular gene therapy: an overview. Clin Exp Ophthalmol. 2021;49(8):786-807.
Cyranoski D. The ethical war over gene editing. Nature. 2015;526(7573):16-7.
European Medicines Agency (EMA). Guidelines on gene therapy medicinal products. 2018. Available from: https://www.ema.europa.eu
chimmer J, Breazzano S. Gene therapy’s next revolution: innovation and access. Nat Biotechnol. 2021;39(7):908-11.
High KA, Roncarolo MG. Gene therapy. N Engl J Med. 2019;381(5):455-64.
Liao Y, Xie N, Yin F, Li F, Qi J, Li X, et al. Combining CRISPR/Cas9 and immune checkpoint inhibitors for cancer therapy. J Exp Clin Cancer Res. 2020;39(1):1-14.
Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217-21.
Mout R, Ray M, Yesilbag Tonga G, Lee YW, Tay T, Sasaki K, et al. Direct cytosolic delivery of CRISPR/Cas9-Ribonucleoprotein for efficient gene editing. ACS Nano. 2017;11(3):2452-8.
Shendure J,Findlay GM,Snyder MW.Genomic medicine–progress,pitfalls, and promise.Cell. 2019;177(1):45-57.
Tsai SQ, Zheng Z, Nguyen NT, Liebers M, Topkar VV, Thapar V, et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol. 2015;33(2):187-97.
Ledford H. CRISPR treatment inserted directly into the body for first time. Nature. 2020;579(7799):185.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Muhammad Sidharta Krisna, Muhammad Alfi Reza, Bobby Aksanda Putra, Bukhari Muslim Siregar, Muhammad Alif Adhani
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
